Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar

Executive Summary

An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.

You may also be interested in...



Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes

Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.

FDA Clears Lupin API Site Of NDMA Risk, Compliance Efforts Ongoing

Lupin’s Tarapur API site for ‘sartans’, including valsartan, has been cleared of NDMA concerns by the US FDA, and the Indian firm has also provided analytical reports to EU authorities to affirm its case. The FDA inspection, though, did end with a lone observation at the site.

Perrigo Generic Of Teva's ProAir Stunned By Another FDA CRL

Perrigo has got another Complete Response Letter on its generic version of Teva's ProAir, the company’s fourth to date, prompting a cut in its 2018 EPS guidance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123571

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel